Published in JAMA on December 17, 2003
Does the pharmaceutical industry influence guidelines?: two examples from Germany. Dtsch Arztebl Int (2013) 3.78
Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov (2010) 2.27
Psoriasis assessment tools in clinical trials. Ann Rheum Dis (2005) 2.24
Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis (2005) 2.24
Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev (2009) 1.66
Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis (2005) 1.56
The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes (2006) 1.31
Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs (2010) 1.31
AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes. Proc Natl Acad Sci U S A (2006) 1.20
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J (2007) 1.19
Impaired Langerhans cell migration in psoriasis. J Exp Med (2006) 1.16
Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis (2007) 1.11
Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech (2012) 1.09
Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther (2014) 1.08
Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol (2008) 1.02
Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model. Front Immunol (2015) 0.97
LFA-1 affinity regulation is necessary for the activation and proliferation of naive T cells. J Biol Chem (2009) 0.97
Update on the natural history and systemic treatment of psoriasis. Adv Dermatol (2008) 0.96
Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf (2012) 0.94
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res (2007) 0.94
The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis (2015) 0.91
The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res (2006) 0.90
Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes (2008) 0.90
Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol (2005) 0.88
Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study. Arch Drug Inf (2010) 0.86
Psoriasis. Cold Spring Harb Perspect Med (2014) 0.85
New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression. Ann N Y Acad Sci (2010) 0.84
Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn's Disease: an open-label pilot study. Dig Dis Sci (2010) 0.83
Psoriasis: advances in pathophysiology and management. Postgrad Med J (2007) 0.82
Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial. Arch Drug Inf (2010) 0.82
Efalizumab in the treatment of psoriasis. Biologics (2007) 0.82
Placebo effects on itch: a meta-analysis of clinical trials of patients with dermatological conditions. J Invest Dermatol (2014) 0.82
Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses. Dermatol Ther (Heidelb) (2012) 0.81
Infliximab (Remicade) in the treatment of psoriatic arthritis. Ther Clin Risk Manag (2006) 0.80
Evaluation of efalizumab using safe psoriasis control. BMC Dermatol (2006) 0.80
The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab. Arch Dermatol Res (2006) 0.80
Assessing long-term drug safety: lessons (re) learned from raptiva. Semin Cutan Med Surg (2010) 0.79
2E8 binds to the high affinity I-domain in a metal ion-dependent manner: a second generation monoclonal antibody selectively targeting activated LFA-1. J Biol Chem (2010) 0.79
Immunobiologics in the treatment of psoriasis. Clin Immunol (2007) 0.79
A promising step forward in psoriasis therapy. JAMA (2003) 0.79
Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study Results. Arch Drug Inf (2009) 0.78
Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy. Invest Ophthalmol Vis Sci (2011) 0.78
Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence. BMC Dermatol (2006) 0.76
Biological agents targeting beyond TNF-alpha. Indian J Crit Care Med (2008) 0.76
Biological drugs targeting the immune response in the therapy of psoriasis. Biologics (2008) 0.76
Disruption of tumour-host communication by downregulation of LFA-1 reduces COX-2 and e-NOS expression and inhibits brain metastasis growth. Oncotarget (2016) 0.75
Biologics in dermatology: an integrated review. Indian J Dermatol (2014) 0.75
Psoriasis (chronic plaque). BMJ Clin Evid (2009) 0.75
Solution structure of a novel T-cell adhesion inhibitor derived from the fragment of ICAM-1 receptor: cyclo(1,8)-Cys-Pro-Arg-Gly-Gly-Ser-Val-Cys. Biopolymers (2009) 0.75
Serum TNF-alpha in psoriasis after treatment with propylthiouracil, an antithyroid thioureylene. BMC Dermatol (2004) 0.75
Tolerance--is it worth it? Cold Spring Harb Perspect Med (2014) 0.75
Biologics in the management of psoriasis. Clin Cosmet Investig Dermatol (2009) 0.75
Efalizumab-induced severe thrombocytopenia can be resolved. Biologics (2008) 0.75
Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial. Arch Drug Inf (2009) 0.75
Immunotargeting in the management of psoriasis. Immunotargets Ther (2013) 0.75
[Biologicals: a new therapeutic approach for inflammatory diseases]. Internist (Berl) (2004) 0.75
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet (2008) 5.85
A randomized trial of epidural glucocorticoid injections for spinal stenosis. N Engl J Med (2014) 5.01
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med (2003) 3.67
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet (2009) 3.55
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet (2003) 3.52
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics (2003) 3.39
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA (2011) 3.29
Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health (2013) 2.82
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med (2010) 2.74
Recent immune status determines the source of antigens that drive homeostatic T cell expansion. J Immunol (2005) 2.73
Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol (2013) 2.58
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A (2005) 2.47
Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J (2008) 2.41
Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol (2013) 2.38
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med (2011) 2.32
International collaborative project to compare and monitor the nutritional composition of processed foods. Eur J Prev Cardiol (2011) 2.17
PSORS2 is due to mutations in CARD14. Am J Hum Genet (2012) 2.10
Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci (2005) 2.06
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol (2004) 2.05
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol (2011) 2.03
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol (2008) 1.99
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet (2011) 1.74
A subset of methylated CpG sites differentiate psoriatic from normal skin. J Invest Dermatol (2011) 1.73
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol (2004) 1.66
Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol (2003) 1.60
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis (2014) 1.60
Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. J Am Acad Dermatol (2004) 1.53
Cardiocutaneous syndromes and associations. J Am Acad Dermatol (2002) 1.53
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol (2013) 1.50
Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. J Invest Dermatol (2008) 1.46
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol (2009) 1.45
Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model. Acad Radiol (2011) 1.45
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs (2009) 1.44
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol (2008) 1.43
Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health (2009) 1.43
Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol (2006) 1.42
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum (2008) 1.41
Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol (2012) 1.40
PsEma--a hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczema. Skinmed (2005) 1.39
Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet (2005) 1.37
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol (2004) 1.36
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol (2005) 1.34
A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol (2002) 1.33
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol (2005) 1.32
Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol (2008) 1.28
Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol (2004) 1.27
The use of cyclosporine in dermatology: part I. J Am Acad Dermatol (2010) 1.26
Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity. J Virol (2006) 1.25
Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum Genet (2002) 1.24
Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol (2012) 1.23
Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis (2010) 1.22
Comorbidities in psoriasis patients. Semin Cutan Med Surg (2010) 1.21
A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med (2011) 1.20
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med (2015) 1.20
Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol (2007) 1.17
Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes (2003) 1.17
Gamma delta T cell homeostasis is controlled by IL-7 and IL-15 together with subset-specific factors. J Immunol (2005) 1.16
Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis (2003) 1.16
Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol (2013) 1.15
Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology (2008) 1.15
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol (2004) 1.15
Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Aff (Millwood) (2007) 1.12
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol (2003) 1.09
The use of cyclosporine in dermatology: part II. J Am Acad Dermatol (2010) 1.07
Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol (2006) 1.07
Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol (2005) 1.07
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol (2011) 1.06
Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther (2003) 1.04
Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol (2004) 1.03
Prevalence, awareness, treatment, and control of hypertension among herdsmen living at 4,300 m in Tibet. Am J Hypertens (2012) 1.02
A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J Drugs Dermatol (2005) 1.01
Update on botulinum toxin for facial aesthetics. Dermatol Clin (2002) 1.01
The case for soluble Aβ oligomers as a drug target in Alzheimer's disease. Trends Pharmacol Sci (2013) 1.00
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis (2013) 1.00
Consumer awareness and self-reported behaviours related to salt consumption in Australia. Asia Pac J Clin Nutr (2010) 0.98
Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol (2013) 0.98
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes (2013) 0.98
Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol (2003) 0.96
Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. J Invest Dermatol (2008) 0.96
Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol (2009) 0.96
Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol (2005) 0.96
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol (2011) 0.95
Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol (2004) 0.94
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol (2010) 0.94
Study protocol: the Back Pain Outcomes using Longitudinal Data (BOLD) registry. BMC Musculoskelet Disord (2012) 0.94
Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol (2005) 0.94
Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics (2005) 0.93
Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS One (2011) 0.92
Psoriatic arthritis: an update. Arthritis (2012) 0.92